Nachrichten zur ATAI Life Sciences NV Aktie

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Lets…

atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the…

ATAI Life Sciences stock soars on Beckley Psytech merger deal By Investing.com

ATAI Life Sciences stock soars on Beckley Psytech merger deal…

atai Life Sciences and Beckley Psytech to merge in all-share deal

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage...…

atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday’s opening bell after it announced it has inked a definitive agreement…

atai Life Sciences expects key trial data by mid-2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress…

atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Lets…

atai Life Sciences could double on positive data from Beckley Psytechs depression therapy: Jefferies

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later…

atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytechs depression therapy

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later…

atai Life Sciences announces positive topline data from treatment-resistant depression study

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of BPL-003, an…

atai Life Sciences announces positive topline data from Phase 2a treatment-resistant depression study

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of…

atai Life Sciences shares gain momentum ahead of pivotal trial readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ stock is poised to climb significantly, driven by a series of clinical catalysts this year…

atai Life Sciences builds clinical momentum in first quarter of 2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key…

atai Life Sciences doses first patient in Phase 2 social anxiety trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of…

atai Life Sciences CEO discusses major data readouts expected through 2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the companys upcoming clinical milestones and strategic focus…

atai Life Sciences entering catalyst-rich period, Jefferies says

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and…

atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and…

atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as…

atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of…

atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech’s Phase 2b trial evaluating BPL-003…

atai Life Sciences completes public offering, raising $63.25M

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter’s option to…

atai Life Sciences announces pricing of $55M public offering of shares

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10…

atai Life Sciences unveils $55M public offering to advance mental health treatments

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The…

atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech’s Phase 2a…

atai Life Sciences reports new BPL-003 trial shows promise for AUD

…

atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout

Positive data from Irish biotechnology firm GH Research’s Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT),…

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

…

atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts

atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for…

atai Life Sciences unveils positive results from Beckley Psytech’s alcohol use disorder trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech’s Phase 2a study of BPL-003 (intranasal 5-MeO-DMT...…

atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health...…

atai Life Sciences shares set to be lifted by 2025 trial results: analysts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in…

atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01

atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies...…

Psychedelic Stock Deep Dive: Atai Life Sciences

…

atai Life Sciences chief scientific officer details VLS-01 trial success

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ chief scientific officer Dr Srinivas Rao joined Proactive to discuss the companys latest clinical trial…

atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a Buy rating from Jefferies analysts as the company’s pipeline of mental health therapies...…

atai life sciences reveals positive clinical trial results and discusses FDA ruling on MDMA

…

atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable…

atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech’s Phase 1 trial of its patient-protected intravenous...…

atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression

…

atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech’s Phase1 trial of its patient-protected intravenous...…

atai Life Sciences poised for success with rigorous clinical trials

Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical…

atai Life Sciences bolsters board with two new directors

atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously…

atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has a pipeline of psychedelic and non-psychedelic drug assets that are poised to create value,…

atai Life Sciences is developing innovative therapies for mental health disorders

Deep Dive - atai Life Sciences…

atai Life Sciences co-founder takes on CEO role after better quarter

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced co-founder Srinivas Rao will take on the CEO role following the resignation of…

atai Life Sciences boss makes way for co-founder after strong quarter

atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao.…

atai Life Sciences boss makes way for co-founder after better quarter

atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao.…

atai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression study

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its…

atai announces publication of Beckley Psytechs Phase 1 study for novel 5-MeO-DMT asset

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytechs Phase 1 study of its novel,…

atai Life Sciences CEO spotlights psychedelic therapy milestones and upcoming catalysts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus…